ReviewBladder cancer (Amsterdam, Netherlands)2020
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.
Review in Bladder cancer (Amsterdam, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.Non-coding RNA research · 2024Review
- A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend?Translational andrology and urology · 2024Review
- Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.Investigative and clinical urology · 2023Review
- Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.The Journal of urology · 2022Article
- Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.Nature reviews. Urology · 2022Review
- Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.Journal of cancer research and clinical oncology · 2021Article
- Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.Urologic oncology · 2021Article
- Advances in bladder cancer biology and therapy.Nature reviews. Cancer · 2021Review
- [Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance].Der Urologe. Ausg. A · 2021Review
- Clinical Perspectives of ERCC1 in Bladder Cancer.International journal of molecular sciences · 2020Review
- Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2020Review
- Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.Nature reviews. Urology · 2020Review
- Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.JAMA oncology · 2018Article
- Computational pathology in bladder cancer: A scoping review.Bladder cancer (Amsterdam, Netherlands)Review
- Emerging perioperative therapeutic approaches in muscle invasive bladder cancer.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
SWOG1314 is a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. COXEN is a biomarker approach in which predictive biomarkers are developed using
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.